Xu, Y., Wu, Y., Dai, Y., Ji, X., Cui, Z., Zhu, X., Xu, Y. (2025). Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.151